公开(公告)号：WO2014176235A2

公开(公告)日：2014-10-30

申请号：PCT/US2014034948

申请日：2014-04-22

Applicant: ENZO BIOCHEM INC ,  NUSSENBLATT RICHARD ,  LIU BAOYING ,  WEI LAI ,  RABBANI ELAZAR ,  DONEGAN JAMES J

Inventor： NUSSENBLATT RICHARD ,  LIU BAOYING ,  WEI LAI ,  RABBANI ELAZAR ,  DONEGAN JAMES J

IPC: A61K35/14 ,  G01N33/50

CPC classification number: A61K35/17 ,  C12N5/0636 ,  C12N2501/998 ,  G01N33/505

Abstract: The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age-related macular degeneration and uveitis.

Abstract translation: 本公开涉及鉴定包含在患有自身免疫疾病的患者中诱导免疫耐受的表位的化合物的方法。 本公开还涉及通过施用（i）通过本文所述的方法鉴定的化合物，（ii）来自患者或相容供体的调节性T细胞，或（iii）调节性T细胞的组合来治疗自身免疫性疾病的方法， 细胞和通过本文所述方法鉴定的化合物。 本发明还涉及治疗年龄相关性黄斑变性和葡萄膜炎的方法。

公开(公告)号：WO2012103187A3

公开(公告)日：2012-11-22

申请号：PCT/US2012022511

申请日：2012-01-25

Applicant: US HEALTH ,  WEI LAI ,  NUSSENBLATT ROBERT ,  LIU BAOYING ,  CHAN CHI-CHAO

Inventor： WEI LAI ,  NUSSENBLATT ROBERT ,  LIU BAOYING ,  CHAN CHI-CHAO

IPC: C12Q1/68 ,  A61K38/17 ,  G01N33/50

CPC classification number: C12Q1/6883 ,  A61K38/1793 ,  C12Q2600/154 ,  G01N33/6893 ,  G01N2333/54 ,  G01N2440/12 ,  G01N2800/164 ,  G01N2800/50

Abstract: The present invention is directed to methods of diagnosing the presence, severity, or predisposition for development of age-related macular degeneration in a patient based on the frequency of IL-17RC+ cells and or methylation of the promoter of lL17RC gene. Methods of treated age-related macular degeneration are also described.

Abstract translation: 本发明涉及基于IL-17RC +细胞的频率和lL17RC基因的启动子甲基化来诊断患者年龄相关性黄斑变性的存在，严重程度或倾向性的方法。 还描述了治疗年龄相关性黄斑变性的方法。

公开(公告)号：WO2014176555A3

公开(公告)日：2014-10-30

申请号：PCT/US2014/035549

申请日：2014-04-25

Applicant: ENZO BIOCHEM, INC. ,  NUSSENBLATT, Richard ,  LIU, Baoying ,  WEI, Lai ,  RABBANI, Elazar ,  DONEGAN, James, J.

Inventor： NUSSENBLATT, Richard ,  LIU, Baoying ,  WEI, Lai ,  RABBANI, Elazar ,  DONEGAN, James, J.

IPC: A61K39/00 ,  A61K39/38 ,  C40B30/04 ,  G01N33/00

Abstract: The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age- related macular degeneration and uveitis. The disclosure also relates to methods of monitoring, diagnosing and/or prognosticating an autoimmune disease in a patient.

公开(公告)号：WO2014176235A3

公开(公告)日：2014-10-30

申请号：PCT/US2014/034948

申请日：2014-04-22

Applicant: ENZO BIOCHEM, INC. ,  NUSSENBLATT, Richard ,  LIU, Baoying ,  WEI, Lai ,  RABBANI, Elazar ,  DONEGAN, James, J.

Inventor： NUSSENBLATT, Richard ,  LIU, Baoying ,  WEI, Lai ,  RABBANI, Elazar ,  DONEGAN, James, J.

IPC: A61K39/00 ,  A61K39/38 ,  C40B30/04 ,  G01N33/00

Abstract: The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age-related macular degeneration and uveitis.

公开(公告)号：WO2012094300A3

公开(公告)日：2012-09-27

申请号：PCT/US2012020050

申请日：2012-01-03

Applicant: US HEALTH ,  NUSSENBLATT ROBERT ,  LIU BAOYING ,  WEI LAI

Inventor： NUSSENBLATT ROBERT ,  LIU BAOYING ,  WEI LAI

IPC: A61K39/395 ,  A61P27/00 ,  A61P27/02

CPC classification number: A61K39/3955 ,  A61K2039/505 ,  C07K16/244 ,  G01N33/573 ,  G01N33/6863 ,  G01N33/6893

Abstract: The present invention is directed to methods of treating and diagnosing age-related macular degeneration.

Abstract translation: 本发明涉及治疗和诊断年龄相关性黄斑变性的方法。

公开(公告)号：WO2012094300A2

公开(公告)日：2012-07-12

申请号：PCT/US2012/020050

申请日：2012-01-03

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services Office of Technology Transfer National Institutes of Health ,  NUSSENBLATT, Robert ,  LIU, Baoying ,  WEI, Lai

Inventor： NUSSENBLATT, Robert ,  LIU, Baoying ,  WEI, Lai

IPC: A61K39/395 ,  A61P27/02 ,  A61P27/00

CPC classification number: A61K39/3955 ,  A61K2039/505 ,  C07K16/244 ,  G01N33/573 ,  G01N33/6863 ,  G01N33/6893

Abstract: The present invention is directed to methods of treating and diagnosing age-related macular degeneration.

Abstract translation: 本发明涉及治疗和诊断年龄相关性黄斑变性的方法。

公开(公告)号：WO2016014535A1

公开(公告)日：2016-01-28

申请号：PCT/US2015/041337

申请日：2015-07-21

Applicant: NOVARTIS AG ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  BROGDON, Jennifer ,  EBERSBACH, Hilmar ,  GILL, Saar ,  GLASS, David ,  JASCUR, Julia ,  KENDERIAN, Saad ,  MANNICK, Joan ,  MILONE, Michael, C. ,  MURPHY, Leon ,  RICHARDSON, Celeste ,  SINGH, Reshma ,  WEI, Lai ,  WU, Qilong ,  YANG, Qiumei ,  ZHANG, Jiquan

Inventor： BROGDON, Jennifer ,  EBERSBACH, Hilmar ,  GILL, Saar ,  GLASS, David ,  JASCUR, Julia ,  KENDERIAN, Saad ,  MANNICK, Joan ,  MILONE, Michael, C. ,  MURPHY, Leon ,  RICHARDSON, Celeste ,  SINGH, Reshma ,  WEI, Lai ,  WU, Qilong ,  YANG, Qiumei ,  ZHANG, Jiquan

IPC: A61K35/17 ,  C07K14/725 ,  C07K16/28

CPC classification number: A61K39/0011 ,  A61K31/7068 ,  A61K35/17 ,  A61K45/06 ,  A61K2039/5156 ,  C07K14/7051 ,  C07K14/70578 ,  C07K16/2851 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

Abstract translation: 本发明提供了治疗与CLL-1表达相关的疾病的组合物和方法。 本发明还涉及对CLL-1特异性的嵌合抗原受体（CAR），编码它的载体和包含CLL-1 CAR的重组细胞。 本发明还包括施用基因修饰的表达包含CLL-1结合结构域的CAR的细胞的方法。

公开(公告)号：WO2014176555A2

公开(公告)日：2014-10-30

申请号：PCT/US2014035549

申请日：2014-04-25

Applicant: ENZO BIOCHEM INC ,  NUSSENBLATT RICHARD ,  LIU BAOYING ,  WEI LAI ,  RABBANI ELAZAR ,  DONEGAN JAMES J

Inventor： NUSSENBLATT RICHARD ,  LIU BAOYING ,  WEI LAI ,  RABBANI ELAZAR ,  DONEGAN JAMES J

IPC: A61K35/14 ,  G01N33/50

CPC classification number: A61K35/17 ,  C12N5/0636 ,  C12N2501/998 ,  G01N33/505

Abstract: The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age- related macular degeneration and uveitis. The disclosure also relates to methods of monitoring, diagnosing and/or prognosticating an autoimmune disease in a patient.

Abstract translation: 本公开涉及鉴定包含在患有自身免疫性疾病的患者中诱导免疫耐受性的表位的化合物的方法。 本公开还涉及通过施用（i）通过本文所述方法鉴定的化合物，（ii）来自患者或相容供体的调节性T细胞，或（iii）调节性T细胞的组合来治疗自身免疫性疾病的方法， 细胞和通过本文所述方法鉴定的化合物。 本公开还涉及治疗年龄相关性黄斑变性和葡萄膜炎的方法。 本公开还涉及监测，诊断和/或预测患者中的自身免疫疾病的方法。

公开(公告)号：WO2012103187A2

公开(公告)日：2012-08-02

申请号：PCT/US2012/022511

申请日：2012-01-25

Applicant: THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  WEI, Lai ,  NUSSENBLATT, Robert ,  LIU, Baoying ,  CHAN, Chi-chao

Inventor： WEI, Lai ,  NUSSENBLATT, Robert ,  LIU, Baoying ,  CHAN, Chi-chao

IPC: C12Q1/68 ,  G01N33/50 ,  A61K38/17

CPC classification number: C12Q1/6883 ,  A61K38/1793 ,  C12Q2600/154 ,  G01N33/6893 ,  G01N2333/54 ,  G01N2440/12 ,  G01N2800/164 ,  G01N2800/50

Abstract: The present invention is directed to methods of diagnosing the presence, severity, or predisposition for development of age-related macular degeneration in a patient based on the frequency of IL-17RC+ cells and or methylation of the promoter of lL17RC gene. Methods of treated age-related macular degeneration are also described.

Abstract translation: 本发明涉及基于IL-17RC +细胞的频率和/或启动子的甲基化诊断患者中年龄相关性黄斑变性的发生，严重性或倾向的方法 的IIL17RC基因。 还描述了治疗的年龄相关性黄斑变性的方法。

公开(公告)号：WO2016115482A1

公开(公告)日：2016-07-21

申请号：PCT/US2016/013637

申请日：2016-01-15

Applicant: NOVARTIS PHARMA AG ,  NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. ,  CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  BROGDON, Jennifer ,  EBERSBACH, Hilmar, Erhard ,  GLASS, David ,  HUBER, Thomas ,  JASCUR, Julia ,  JUNE, Carl, H. ,  LEE, Jihyun ,  MANNICK, Joan ,  MILONE, Michael, C. ,  MURPHY, Leon ,  POSEY, Avery, D. ,  SONG, Huijuan ,  WANG, Yongqiang ,  WEI, Lai ,  WU, Qilong ,  YANG, Qiumei ,  ZHANG, Jiquan

Inventor： BROGDON, Jennifer ,  EBERSBACH, Hilmar, Erhard ,  GLASS, David ,  HUBER, Thomas ,  JASCUR, Julia ,  JUNE, Carl, H. ,  LEE, Jihyun ,  MANNICK, Joan ,  MILONE, Michael, C. ,  MURPHY, Leon ,  POSEY, Avery, D. ,  SONG, Huijuan ,  WANG, Yongqiang ,  WEI, Lai ,  WU, Qilong ,  YANG, Qiumei ,  ZHANG, Jiquan

IPC: C07K14/705 ,  A61K35/17 ,  C07K16/28

CPC classification number: C07K16/2863 ,  A61K35/17 ,  A61K48/0058 ,  A61K2035/124 ,  A61P35/00 ,  A61P35/02 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/28 ,  C07K16/30 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N15/86 ,  C12N2740/10043 ,  C12N2740/15043 ,  C12N2800/60

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Abstract translation: 本发明提供用于治疗与本文所述的肿瘤抗原表达相关的疾病的组合物和方法。 本发明还涉及包含与本文所述的肿瘤抗原特异性的嵌合抗原受体（CAR）可操作地连接的截短的PGK启动子的核酸，以及编码本发明的载体的重组T细胞和包含本发明的CAR的重组T细胞。 本发明还包括施用表达CAR的遗传修饰的T细胞的方法，其包含如本文所述结合肿瘤抗原的抗原结合结构域。